Squamous cell lesions and cancer

Similar documents
Cervical Cancer Screening and Management Guidelines: Changing Again, Huh?

Explanation of your PAP smear

Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium

Liquid-based cytology

PROPERTY OF ELSEVIER SAMPLE CONTENT - NOT FINAL ABNORMAL PAP SMEAR (ABNORMAL CERVICAL CYTOLOGIC FINDINGS) Kathleen Dor

Diagnostic Challenge. Department of Pathology,

Pap smears, cytology and CCHC lab work and follow up

INFLAMMATION AND REACTIVE CHANGES IN CERVICAL EPITHELIUM

Cancer of the Cervix

Basic Professional Training Program for Associate Medical Technologist

Management of Abnormal PAP Smears. K Chacko, MD, FACP 2010 GIM Conference

Management of Abnormal Pap Smear Clinical Practice Guideline

NATIONAL GUIDELINE FOR CERVICAL CANCER SCREENING PROGRAMME

The society for lower genital tract disorders since 1964.

CXCA-MSP. The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics.

Cervical Cancer Screening Guideline

The Cervical Screening Manual

American Academy of Family Physicians

HUMAN PAPILLOMAVIRUS (HPV) FACT SHEET

HPV OncoTect E6, E7 mrna Kit A highly specific molecular test for early detection of cervical cancer

GLOBAL CONCERNS ABOUT HPV VACCINES FACT SHEET

Testing for HPV as an Objective Measure for Quality Assurance in Gynecologic Cytology

NHS Cervical Screening Programme Achievable standards, Benchmarks for reporting, and Criteria for evaluating cervical cytopathology

Cervical Cancer The Importance of Cervical Screening and Vaccination

GUIDELINE DOCUMENT CERVICAL CANCER SCREENING IN SOUTH AFRICA 2015

Protocol for an integrated data request of test results from the laboratories of pathological anatomy. SNOMED 3.5VF - users version January 2016

HPV and the Future of Cervical Screening

Abnormal Pap Smear Tracking in General Internal Medicine Clinic

Breast Fine Needle Aspiration Cytology Reporting : A Study of Application of Probabilistic Approach

Cervical Screening and HPV Vaccine Guidelines In Saudi Arabia. Prof. Mohammed Addar Chairmen Gyneoncology section KKUH, King Saud University

Screening for Cancer of the Cervix

Information Model Requirements of Post-Coordinated SNOMED CT Expressions for Structured Pathology Reports

CERVICAL AND VAGINAL CYTOLOGY Edmund S. Cibas

Carcinosarcoma of the Ovary

worry When to Cervical Abnormalities CME Workshop What s the situation? What are the trends? By Dianne Miller, MD, FRCSC In this article:

SCREENING FOR CANCER OF THE CERVIX

Cytology of Lymph Nodes

Routine Vaginal Cuff Smear Testing in Post Hysterectomy Patients With Benign Uterine Conditions: When Is It Indicated?

The Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.

XI International Workshop of Lower Genital Tract Pathology HPV Disease: The global battle Rome April 2012

Cervical Cancer. Cervical smear test. The cervix. Dysplasia. Cervical cancer. The female reproductive system

HPV testing in the follow-up of women post colposcopy treatment

Cervical Dysplasia and HPV.

Cervical Cancer Prevention and Early Detection What is cervical cancer?

Cervical Cancer Screening. Clinical Practice Guidelines for Average Risk Women

P16INK4A and MIB-1 Expression in Preneoplasia and Neoplasia of Cervix

2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors

Classification of squamous cell cervical cytology. Luz Helena Camargo Casallas

Dr Julia Palmer BAC Annual Scientific Meeting October 2015 THE IMPACT OF HPV PRIMARY SCREENING ON COLPOSCOPY.

Sage Screening Program. Provider Manual

Colposcopic Management of Abnormal Cervical Cytology and Histology

Guidelines for reporting histopathology of cervical carcinoma

Protocol for the Examination of Specimens From Patients With Carcinoma of the Uterine Cervix

Understanding. Cervical Changes A Health Guide for Women. National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Nicole Kounalakis, MD

HPV, Cervical Dysplasia and Cancer

ALABAMA BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM PROVIDER MANUAL

Cytopathology Case Presentation #8

Examples of good screening tests include: mammography for breast cancer screening and Pap smears for cervical cancer screening.

Genital Human Papillomavirus. Patti E. Gravitt, PhD Johns Hopkins University

OBJECTIVES By the end of this segment, the community participant will be able to:

The Diagnosis of Cancer in the Pathology Laboratory

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

ATLAS OF HEAD AND NECK PATHOLOGY THYROID PAPILLARY CARCINOMA

Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology

Breast and Cervical Cancer Treatment Program (BCCTP) Application Guide

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Cervical Cancer Screening

PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT

Multiple Primary and Histology Site Specific Coding Rules KIDNEY. FLORIDA CANCER DATA SYSTEM MPH Kidney Site Specific Coding Rules

2015 RN.ORG, S.A., RN.ORG, LLC

Innersense Voice 139 Jan 15, 2013 Screen to Prevent: Cervical & Prostate Cancer

Polyps. Hyperplasias. CAP 2011: Course AP104. The High Risk Benign Endometrium. Mutter and Nucci 1

LDMAS (LOH Data Management and Analysis Software) User Guide

Introduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause.

Making Sense of Your Pap and HPV Test Results

IMMEDIATE HOT LINE: Effective March 2, 2015

CHAPTER 5. Tumours of the Uterine Cervix

The Pap Smear: Guidelines for Screening and Follow-up

Breast Imaging Made Brief and Simple. Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA

R-16: Chronic nonspecific cervisit

EIN. (Endometrial Intraepithelial Neoplasia): Improved Criteria for diagnosing endometrial precancer. Stanley J. Robboy, MD, FCAP,

PathoBasic - Vulva, Vagina, Cervix. E.Obermann

Classificazioni citologiche: verso uno schema internazionale unificato?

SCD Case Study. Most malignant lesions of the tonsil are either lymphosarcoma or carcinoma.

HUMAN PAPILLOMAVIRUS (HPV) TESTING

Interpretation Guide for Ventana INFORM HPV Probes In Situ Hybridization (ISH) Staining of Cervical Tissue

Case of the. Month October, 2012

P ROGRAMMATIC G UIDELINES FOR S CREENING FOR C ANCER OF THE C ERVIX I N C ANADA

NHS Cervical Screening Having a colposcopy

TAKING SAMPLES FOR CERVICAL SCREENING. A Resource Pack for Trainers

THE CYTOLOGY LABORATORY

A Statistical Analysis of Rescreening Alarms

FocalPoint guided screening

Cervical cancer screening with the HPV test and the Pap test in women ages 30 and older

HPV Human Papillomavirus

MAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER

Cervical Screening Programme

Pleural and Pericardial fluids a one year analysis

HPV DNA-Chip. PapilloCheck HPV-Screening. DNA-Chip for the genotyping of 24 types of genital HPV

Transcription:

Squamous cell lesions and cancer

TBS 2001

Low-grade squamous intraepithelial lesion (LSIL) TBS 2001, BSCC: cellular changes associated with HPV (cytopathic thi effect) and mild dysplasia Muenchner Nomenklatur II Cytopathic effect: II Mild dysplasia: IIID together with moderate dysplasia

LSIL Mod. da Doorbar G.Negri, AP Bolzano

LSIL 85% are associated with HR-HPV HPV 70% regress spontaneously within 2 years 15-25% have a histology of CIN2+

Low-grade squamous intraepithelial lesion (LSIL) Histologically: Condyloma, mild dysplasia, CIN1 Lack of maturation in the lower third of the epithelium Koilocytes may be present in the upper epithelial layers G.Negri, Pathologie Bozen

Low-grade squamous intraepithelial lesion (LSIL) Large mature epithelial cells, single or in sheets Nuclear enlargement more than 3x; hyperchromasia is common, granular or smudged chromatin, nucleoli absent. Nuclear membrane usually smooth or slightly irregular. Multinucleation may be present. Koilocytosis: perinuclear cavitation may be present. Must be associated with nuclear atypia

G.Negri, AP Bolzano

G.Negri, AP Bolzano

G.Negri, AP Bolzano

ASC-US Superficial or intermediate cells DD LSIL Enlarged nuclei (2,5-3x) Minimal hyperchromasia and shape irregularity HPV test may be useful G.Negri, AP Bolzano

HSIL Mod. da Doorbar

High-grade squamous intraepithelial lesion (HSIL) Histologically: moderate and severe dysplasia, yp CIN2 and CIN3 Maturation completely lost or only evident in the upper third of the epithelium. Particularly l in CIN2, Koilocytes and parakeratosis on the surface may be present in the upper epithelial layers

High-grade squamous intraepithelial lesion (HSIL) TBS 2001, BSCC: moderate and severe dysplasia, carcinoma in-situ it (CIN2-3) Muenchner Nomenklatur II Moderate dysplasia: IIID Severe dysplasia: IV

High-grade squamous intraepithelial lesion (HSIL) Medium-sized to small epithelial cells, single or in sheets, in CP occasionally with indian filing Variable nuclear enlargement, with increase of the n/c ratio. Variability of shape and size are typical. Deep indentations and grooves of the nuclear membrane are pathognomonic. Hyperchromasia is typical, however hypochromatic HSILs may occur. Chromatin may be fine or coarsely granular, nucleoli are usually absent Cytoplasm may have metaplastic features.

G.Negri, AP Bolzano

G.Negri, AP Bolzano

G.Negri, Pathologie Bozen

G.Negri, AP Bolzano

G.Negri, AP Bolzano

G.Negri, AP Bolzano

Pale HSIL

HSIL with metaplastic features

ASC-H -usually few abnormal small cells with slightly enlarged nuclei - DD metaplastic cells G.Negri, AP Bolzano G.Negri, AP Bolzano

HSIL dd AIS

SIL of indeterminate grade G.Negri, AP Bolzano

Cervical carcinogenesis HPV infection Productive phase L1 Disregulation - proliferation p16, HPV RNA, proliferation markers

L1 P16/Ki67

Value of p16(ink4a) as a marker of progression/regression in cervical intraepithelial neoplasia grade 1. del Pino M, Garcia S, Fusté V, Alonso I, Fusté P, Torné A, Ordi J. Am J Obstet Gynecol. 2009 Nov;201(5):488.e1-7. OBJECTIVE: The objective of this study was to evaluate the usefulness of p16(ink4a) staining to classify cervical intraepithelial neoplasia grade 1 according to its progression/regression risk. STUDY DESIGN: Patients with a histologic diagnosis of cervical intraepithelial neoplasia grade 1 were prospectively recruited (n = 138). Simultaneous detection of high-risk human papillomaviruses and p16(ink4a) evaluation were performed. Follow-up was conducted every 6 months by cytology and colposcopy and annually by high-risk human papillomavirus testing, for at least 12 months (mean, 29.0). Progression was defined d as a histologic i diagnosis i of cervical intraepithelial neoplasia grades 2-3, regression as a negative cytology and high-risk human papillomaviruses, and persistence as a cytologic result of low-grade squamous intraepithelial lesions and/or a positive test for high-risk human papillomaviruses. RESULTS: Progression was observed in 14 women (10.1%), 66 (47.6%) regressed, and 58 (42.0%) had a persistent disease. p16(ink4a) was positive in 77 (55.8%) initial biopsy specimens. Progression to cervical intraepithelial neoplasia grades 2-3 was identified d in 14 of 77 (18.2%) women with positive and none of 61 (0.00%) women with negative p16(ink4a) immunostaining (P <.001). CONCLUSION: p16(ink4a) negative cervical intraepithelial neoplasia grade 1 lesions rarely yprogress and may benefit from a less intensive follow-up.

HSIL with features suspicious for invasion HSIL with high atypia or keratinization without tumor diathesis Features suggesting g tumor diathesis in classical HSIL G.Negri, Pathologie Bozen

Squamous cell carcinoma Irregular aggregates g and atypical single cells Marked atypia with irregular cell and nuclear shape. Keratinization may be present. Irregular chromatin with nuclear clearing and nucleoli, li particularly l in nonkeratinizing cancer. Tumor diathesis particularly in non-keratinizing cancer. G.Negri, Pathologie Bozen

G.Negri, AP Bolzano

G.Negri, AP Bolzano

G.Negri, AP Bolzano

Tumor diathesis CP LBC G.Negri, Pathologie Bozen

G.Negri, Pathologie Bozen

G.Negri, Pathologie Bozen

G.Negri, AP Bolzano

G.Negri, AP Bolzano